Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||SN-38 + Veliparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|SN-38||SN 38||TOPO Inhibitor (Pan) 3||SN-38 is a metabolite of the topoisomerase inhibitor irinotecan, which causes cell cycle arrest and apoptotic induction, potentially leading to tumor growth inhibition (PMID: 21609311).|
|Veliparib||ABT-888||PARP Inhibitor (Pan) 22||Veliparib (ABT-888) is a PARP1 and PARP2 inhibitor, which inhibits DNA repair and induces lethality in homologous recombination deficient cells, and may enhance the sensitivity of chemotherapeutic agents (PMID: 26251615, PMID: 31074636, PMID: 32452601).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Ewing sarcoma||not applicable||SN-38 + Veliparib||Preclinical||Actionable||In a preclinical study, Ewing sarcoma cells treated with SN-38 combined with Veliparib (ABT-888) resulted in synergism, demonstrating reduced cell viability in culture (PMID: 26438158).||26438158|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|